SFM
NBIX icon

Systematic Financial Management’s Neurocrine Biosciences NBIX Stock Holding History

Systematic Financial Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,891
Closed -$191K – 281
2023
Q1 		$191K Buy
+1,891
New +$197K 0.01% 241

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Systematic Financial Management's NBIX Position: Q2 2023 in Review

Systematic Financial Management sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 1,891 shares — an estimated $191K sold.

Systematic Financial Management first reported a position in NBIX in Q1 2023 and held it in 1 quarter. The position peaked at $191K in Q1 2023. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

  • Systematic Financial Management reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
  • Systematic Financial Management sold 1,891 Neurocrine Biosciences shares in Q2 2023, an estimated $191K.
  • Systematic Financial Management first reported a position in Neurocrine Biosciences in Q1 2023 and held it in 1 quarter.
  • Systematic Financial Management's Neurocrine Biosciences position peaked at $191K in Q1 2023.
  • 456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Systematic Financial Management's 13F filing for Q2 2023, filed 14 Aug 2023.